e-learning
resources
Barcelona 2013
Monday, 09.09.2013
Acute respiratory failure, ARDS and severe COPD exacerbations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prognostic value of urokinase plasminogen activator receptor (uPAR) and neutrophil CD64 expression in acute respiratory distress syndrome patients
A. Attia, H. Hassan, M. Elsammak (Zagazig, Egypt; Dammam, Saudi Arabia)
Source:
Annual Congress 2013 –Acute respiratory failure, ARDS and severe COPD exacerbations
Session:
Acute respiratory failure, ARDS and severe COPD exacerbations
Session type:
Thematic Poster Session
Number:
2430
Disease area:
Respiratory critical care
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Attia, H. Hassan, M. Elsammak (Zagazig, Egypt; Dammam, Saudi Arabia). Prognostic value of urokinase plasminogen activator receptor (uPAR) and neutrophil CD64 expression in acute respiratory distress syndrome patients. Eur Respir J 2013; 42: Suppl. 57, 2430
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Usefulness of a selective neutrophil elastase inhibitor and a recombinant human soluble thrombomodulin in patients with ARDS and DIC
Source: Annual Congress 2013 –Acute respiratory failure, ARDS and severe COPD exacerbations
Year: 2013
Del-1 reduces endotoxin-induced polymorphonuclear leukocytes adhension and mortality
Source: Annual Congress 2013 –Experimental models in critical care
Year: 2013
LATE-BREAKING ABSTRACT: The metalloproteinase ADAM8 promotes acute and chronic lung inflammation
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015
Ventilation-induced neutrophil infiltration depends on nuclear factor-kB and NF-kB repressing factor
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Preoperative statin administration does not protect against early postoperative acute respiratory distress syndrome (ARDS): A retrospective cohort study
Source: Annual Congress 2013 –Acute respiratory failure, ARDS and severe COPD exacerbations
Year: 2013
Markers of poor outcome in patients with acute hypoxemic respiratory failure
Source: International Congress 2014 – ICU outcomes, sepsis and infections
Year: 2014
Outcome of acute drug-induced pneumonias in ICU
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Heparin effect in pulmonary cell populations in an in-vitro model of acute lung injury
Source: International Congress 2016 – Studies in airway cell biology
Year: 2016
Can procalcitonin or C-reactive protein predict supporative lung complications and ARDS at severe community-acquired pneumonia (CAP)?
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Methotrexate reduces acute lung injury in a murine model of sepsis
Source: International Congress 2016 – Infections, sepsis, and pulmonary embolism
Year: 2016
Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease
Source: International Congress 2017 – Current challenges in COPD evaluation
Year: 2017
Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015
Heparin effect in alveolar cells and macrophages in an acute lung injury model
Source: International Congress 2015 – Novel insights into the pathobiology of acute lung injury
Year: 2015
The role of SIRT1 in LPS-induced lung endothelial barrier dysfunction and lung injury in vivo
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016
Obesity modulates the alveolar macrophage response
Source: International Congress 2015 – Novel insights into the pathobiology of acute lung injury
Year: 2015
Acute respiratory distress syndrome in patients admitted for community-acquired pneumonia
Source: International Congress 2014 – ARDS, skeletal muscles, physiology and weaning
Year: 2014
LATE-BREAKING ABSTRACT: Activation of MTOR in pulmonary epithelium promotes LPS-induced acute lung injury
Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease
Year: 2016
Down-regulation of RIP140 can prevent LPS-induced inflammation and acute lung injury in mice via PPARγ
Source: International Congress 2015 – Novel insights into the pathobiology of acute lung injury
Year: 2015
Drug-associated acute respiratory distress syndrome: A prospective observational cohort study
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept